Uncategorized

Cut, Keep, or Cash In: The Pharmaceutical Patent Decision Matrix That Separates Winning Portfolios from Expensive Archives

Pharma patent strategy is entering a new era: stop treating every patent like a winner. Start treating it like a portfolio.
If you’re building a pharmaceutical IP strategy today, you’re probably still asking the same question—“Do we have a patent?”
B…

Cut, Keep, or Cash In: The Pharmaceutical Patent Decision Matrix That Separates Winning Portfolios from Expensive Archives Read Post »

Uncategorized

Business Development Guide for Commercial & Market Access Vendors: Sell Before the Drug Patent Clock Runs Out

The clock is ticking—so why are so many commercial market access teams waiting until after the patent clock runs out?
In pharma, timing isn’t just strategy—it’s survival.
A lot of business development (BD) in commercial market access still behaves like…

Business Development Guide for Commercial & Market Access Vendors: Sell Before the Drug Patent Clock Runs Out Read Post »

Biotechblog
Scroll to Top